MIM
KALV

Monashee Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

Monashee Investment Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-264,111
Closed -$3.89M – 35
2022
Q1 		$3.89M Sell
264,111
-35,889
-12% -$516K 1.13% 9
2021
Q4 		$3.97M Buy
300,000
+175,000
+140% +$2.79M 0.98% 17
2021
Q3 		$2.18M Buy
+125,000
New +$2.53M 0.4% 59
2018
Q3 		– Hold
0
– – – 70

Other funds holding KALV

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Monashee Investment Management's KALV Position: Q2 2022 in Review

Monashee Investment Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2022, closing a stake of 264,111 shares — an estimated $3.89M sold.

Monashee Investment Management first reported a position in KALV in Q3 2021 and held it in 3 quarters. The position peaked at $3.97M in Q4 2021. 91 funds tracked by Wall St. Rank hold KALV as of Q2 2022.

  • Monashee Investment Management reported no remaining KalVista Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Monashee Investment Management sold 264,111 KalVista Pharmaceuticals shares in Q2 2022, an estimated $3.89M.
  • Monashee Investment Management first reported a position in KalVista Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Monashee Investment Management's KalVista Pharmaceuticals position peaked at $3.97M in Q4 2021.
  • 91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2022.

Based on Monashee Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.